235 related articles for article (PubMed ID: 21744082)
1. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
Butts C; Maksymiuk A; Goss G; Soulières D; Marshall E; Cormier Y; Ellis PM; Price A; Sawhney R; Beier F; Falk M; Murray N
J Cancer Res Clin Oncol; 2011 Sep; 137(9):1337-42. PubMed ID: 21744082
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
[TBL] [Abstract][Full Text] [Related]
3. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
[TBL] [Abstract][Full Text] [Related]
4. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
Wu YL; Park K; Soo RA; Sun Y; Tyroller K; Wages D; Ely G; Yang JC; Mok T
BMC Cancer; 2011 Oct; 11():430. PubMed ID: 21982342
[TBL] [Abstract][Full Text] [Related]
5. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
Sangha R; Butts C
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
[TBL] [Abstract][Full Text] [Related]
6. Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.
Ohyanagi F; Horai T; Sekine I; Yamamoto N; Nakagawa K; Nishio M; Senger S; Morsli N; Tamura T
Jpn J Clin Oncol; 2011 May; 41(5):718-22. PubMed ID: 21393255
[TBL] [Abstract][Full Text] [Related]
7. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
[TBL] [Abstract][Full Text] [Related]
9. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
[TBL] [Abstract][Full Text] [Related]
10. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
North S; Butts C
Expert Rev Vaccines; 2005 Jun; 4(3):249-57. PubMed ID: 16026241
[TBL] [Abstract][Full Text] [Related]
12. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy.
Thongprasert S; Sanguanmitra P; Juthapan W; Clinch J
Lung Cancer; 1999 Apr; 24(1):17-24. PubMed ID: 10403690
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Zhong C; Liu H; Jiang L; Zhang W; Yao F
PLoS One; 2013; 8(3):e58466. PubMed ID: 23555583
[TBL] [Abstract][Full Text] [Related]
14. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
15. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
16. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
Driessen EJM; Schulkes KJG; Dingemans AC; van Loon JGM; Hamaker ME; Aarts MJ; Janssen-Heijnen MLG
Lung Cancer; 2018 Feb; 116():55-61. PubMed ID: 29413051
[TBL] [Abstract][Full Text] [Related]
17. A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Rodriguez PC; Popa X; Martínez O; Mendoza S; Santiesteban E; Crespo T; Amador RM; Fleytas R; Acosta SC; Otero Y; Romero GN; de la Torre A; Cala M; Arzuaga L; Vello L; Reyes D; Futiel N; Sabates T; Catala M; Flores YI; Garcia B; Viada C; Lorenzo-Luaces P; Marrero MA; Alonso L; Parra J; Aguilera N; Pomares Y; Sierra P; Rodríguez G; Mazorra Z; Lage A; Crombet T; Neninger E
Clin Cancer Res; 2016 Aug; 22(15):3782-90. PubMed ID: 26927662
[TBL] [Abstract][Full Text] [Related]
18. Survival of patients with advanced non-small-cell lung cancer at Ubon Ratchathani Cancer Center, Thailand.
Srisam-Ang K; Podhipak A; Narksawat K; Supaattagorn P; Tipayamongkholgul M
Southeast Asian J Trop Med Public Health; 2005 Jul; 36(4):994-1006. PubMed ID: 16295558
[TBL] [Abstract][Full Text] [Related]
19. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
Reck M
Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
